Search Results for: 68

Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and extension into oncology ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the strengthening

– VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy- – Data to be featured in an oral presentation on Monday, May 16 at 5:15 p.m. ET- ROCKVILLE, Md., May 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV) platform- ROCKVILLE, Md., March 28, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallό, Ph.D., appointed as General Director of Synthetic Biologics’ European Subsidiary, transitioning from Chief Operating Officer of VCN Biosciences- ROCKVILLE, Md., March 23, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified

ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a panel discussion entitled “Pancreatic Cancer: Turning the Tide for One of

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET-

– Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration – – Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma and a Phase 2/3 pivotal trial either as an adjunct

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Wednesday, March 16, 2022, at 4:30 p.m. ET to discuss its financial results for